Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Annexin Pharmaceuticals AB currently maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area, consisting of 1 pending office action. This single action is assigned to 1 distinct examiner operating within 1 distinct art unit. This concentration indicates a specific technological focus for the company's current prosecution efforts, as all active matters are localized to a single point of contact within the USPTO. The lack of diversity in examiners and art units simplifies the administrative overhead of tracking multiple different prosecution tracks.
The busiest examiner identified for this portfolio is IANNUZO, NATALIE NMN, who is handling the 1 pending office action. Because the total count of pending actions is limited to this single matter, IANNUZO, NATALIE NMN is responsible for the entirety of the company's current pending workload. This creates a direct relationship between the applicant and the examiner, where the outcome of the entire pending portfolio rests on the interactions within this specific examination pair. Practitioners can focus their strategy on the specific examination practices and precedents of this individual.
The involvement of 1 distinct art unit suggests that the subject matter of the pending application falls within a narrow technical niche of Biotechnology & Pharmaceuticals. For practitioners, this means that prosecution strategy can be tailored specifically to the internal practices of this unit. Managing this portfolio requires a deep understanding of the specific tendencies of the assigned examiner rather than a broad approach across multiple departments. The simplicity of this arrangement allows for a targeted legal approach to the company's current goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 1 | 12.2% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18365712 | PROCESS OF MANUFACTURE OF ANNEXIN V | IANNUZO, NATALIE NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18365712 | PROCESS OF MANUFACTURE OF ANNEXIN V | IANNUZO, NATALIE NMN | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18365712 | PROCESS OF MANUFACTURE OF ANNEXIN V | IANNUZO, NATALIE NMN | 1653 | §103§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnnexin Pharmaceuticals AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Natalie Nmn Iannuzo has the most, with 1 of Annexin Pharmaceuticals AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
